The effectiveness of BP1003 is likely due to its ability to decrease STAT3 levels, which leads to decreased expression of its downstream targets, such as vimentin and Bcl-2, which have both been associated with tumor aggression and poor prognosis. This evidence concerns the gene STAT3 and neoplasm.